OncoACP3

Search documents
BMY Reports Positive Data on Sotyktu From Arthritis Study
ZACKS· 2025-06-12 14:16
Core Insights - Bristol Myers (BMY) announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint, indicating significant efficacy [1][4] - Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor, representing a new class of small molecules and is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases [1][4] - The drug is already approved in numerous countries for the treatment of adults with moderate-to-severe plaque psoriasis [2] Study Results - The phase III POETYK PsA-1 study involved 670 patients and showed a significantly greater proportion of patients treated with Sotyktu achieving ACR20 response compared to placebo at week 16 [4] - Key secondary endpoints met include Psoriasis Area and Severity Index (PASI) 75 response, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) score, and Minimal Disease Activity (MDA) response [5] - The late-stage PsA program includes two phase III trials, POETYK PsA-1 and POETYK PsA-2, with the latter enrolling approximately 730 patients [6] Licensing and Strategic Moves - BMY's subsidiary RayzeBio entered into a $1.35 billion licensing deal with Philochem for the prostate cancer therapy OncoACP3, which includes a $350 million upfront payment and potential milestones of $1 billion [9][10] - BMY is looking to expand its portfolio and pipeline due to generic competition faced by legacy drugs, with a potential label expansion of Sotyktu to broaden its target patient population [11] - A strategic collaboration agreement was announced with BioNTech for the co-development and co-commercialization of the investigational bispecific antibody BNT327 [12] Market Performance - Shares of Bristol Myers have declined by 15.9% over the past three months, while the industry has seen a decline of 5.3% [2] - BMY has experienced pipeline setbacks recently, negatively impacting its share price [13]
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Globenewswire· 2025-06-10 21:55
Core Insights - Philochem AG has entered into a definitive agreement with RayzeBio, granting exclusive worldwide rights to develop, manufacture, and commercialize OncoACP3, a therapeutic and diagnostic agent targeting prostate cancer [1][3] - The agreement includes a $350 million up-front payment and potential additional payments of up to $1.0 billion based on development, regulatory, and commercial milestones, along with mid-single to low double-digit royalties on global net sales [1][3] Company Overview - Philogen Group is a biotechnology company focused on developing pharmaceutical products for highly lethal diseases, utilizing proprietary technologies and a strong portfolio of patents [5] - The company aims to address high unmet medical needs, primarily in oncology, but also has potential applications in chronic inflammatory diseases [5] Product Details - OncoACP3 is a small molecule ligand with high affinity for Acid Phosphatase 3 (ACP3), currently undergoing evaluation in a Phase I trial, showing promising initial data with selective tumor uptake and minimal healthy tissue uptake [2] - IND-enabling activities are ongoing to support a Phase I therapeutic study with Ac-OncoACP3 [2] Strategic Importance - The collaboration with RayzeBio enhances Philochem's position in the radiopharmaceuticals space, aiming to deliver innovative treatments for prostate cancer [3] - This partnership reflects a shared commitment to translating scientific innovation into clinical solutions, potentially making OncoACP3 therapies widely available [3] Transaction Details - The closing of the transaction is subject to regulatory approvals and is expected to finalize in the third quarter of 2025 [4] - Philochem is advised by Centerview Partners UK LLP and Cooley LLP for this transaction [4]